|
Current issue
Archive
Online First
About the journal
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Special Issues
Instructions for authors
Publication charge
Editorial System
Submit your Manuscript
Open access 
|
1/2007
vol. 6 abstract:
IUMPA: The presentation of the aim of using the intrauterine drug delivery system for the hormone preoperative treatment of endometrial cancer and the hormone treatment of abnormal uterine bleeding
Andrzej J. Kowalski
,
Andrzej Zdziennicki
,
Jakub Welfel
,
Grzegorz Surkont
,
Jacek Suzin
Przegląd Menopauzalny 2007; 1: 16–18
Online publish date: 2007/03/02
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Introduction: In the review the intrauterine drug delivery system releasing medroxyprogesterone acetate is shown. This system has been used for preoperative treatment of endometrial cancer and hormone treatment of abnormal uterine bleeding. The system is named IUMPA (IntraUterine MedroxiProgesterone Acetate).
Aim: IUMPA-1 has been prepared for preoperative treatment of endometrial cancer, IUMPA-2 for cases of abnormal bleeding from the uterine cavity. Methods: Medroxyprogesterone acetate was used in both systems. Materials: IUMPA-1 – patients with endometrial cancer, IUMPA-2 – patients with abnormal bleeding. Conclusions: IUMPA-1 was found to be an effective system for preoperative treatment of endometrial cancer. IUMPA-2 only in cases with relative hyperoestrogenism, in which increased administration of progestogen was needed, was successful. In other cases success was not noted. Recapitulation: The Drug Delivery System IUMPA can be used as an alternative or supplementary instrument in selected gynaecological cases. keywords:
endometrial hyperplasia, endometrial cancer, hormone therapy, IUMPA |
 |
